Broad-spectrum anti-infective peptides

Patent metadata

Field	Value
Publication number	US-10351604-B2
Application number	US-201615738730-A
Country	US
Kind code	B2
Filing date	Jun 24, 2016
Priority date	Jun 25, 2015
Publication date	Jul 16, 2019
Grant date	Jul 16, 2019

Abstract

Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.

First claim

What is claimed is:

1. A peptide of 16 to 26 amino acid residues in length comprising the following amino acid sequence: X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S, G or A; X 2 is S or G; X 3 is V or I, X 4 is W or L; X 5 is W, K, A or L; and X 6 is W, K, L or A (SEQ ID NO:12).

2. The peptide of claim 1 , which comprises the following amino acid sequence:
(a) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S or G; X 2 is S or G; X 3 is V; X 4 is W; X 5 is W or K; and X 6 is W, K or A (SEQ ID NO:13);
(b) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S or G; X 2 is S or G; X 3 is V, X 4 is W; X 5 is W; and X 6 is K or A (SEQ ID NO:14);
(c) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S or G; X 2 is S or G; X 3 is V or I, X 4 is W, X 5 is W or A; and X 6 is W or K (SEQ ID NO:15);
(d) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S or G; X 2 is S or G; X 3 is V or I, X 4 is W; X 5 is W, K or A; and X 6 is W, K or A (SEQ ID NO:16);
(e) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S or G; X 2 is S or G; X 3 is V or I, X 4 is W; X 5 is W or A; and X 6 is W, K or A (SEQ ID NO:17); or
(f) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is S or G; X 2 is S or G; X 3 is V or I, X 4 is W; X 5 is W, K or A; and X 6 is W or K (SEQ ID NO:19).

3. The peptide of claim 1 , which comprises the following amino acid sequence:

(SEQ ID NO: 1)

SGSWLRDVWTWLQSKL,

(SEQ ID NO: 2)

GSSWLRDVWTWLQSKL,

(SEQ ID NO: 3)

GSSWLRDVWTWLQSAL,

(SEQ ID NO: 4)

GSSWLRDVWTKLQSWL,

(SEQ ID NO: 5)

GSSWLRDIWTKLQSWL,

(SEQ ID NO: 6)

GSSWLRDIWTALQSWL,

(SEQ ID NO: 7)

GSSWLRDILTALQSLL,

(SEQ ID NO: 8)

AGSWLRDIWTWLQSAL,

or

(SEQ ID NO: 9)

AGSWLRDILTLLQSAL.

4. A pegylated peptide comprising the peptide of claim 1 linked to one, two or more polyethylene glycol (PEG) polymers.

5. A pegylated peptide comprising a peptide of claim 3 linked to one, two or more polyethylene glycol (PEG) polymers.

6. A composition comprising the peptide of claim 1 and a carrier.

7. A pharmaceutical composition comprising an effective amount of the peptide of claim 1 and a pharmaceutically acceptable carrier.

8. A vial containing: (1) a lyophilized composition comprising 200 mg to 300 mg of the peptide of claim 1 , or (2) a pharmaceutical composition, wherein the pharmaceutical composition comprises 200 mg to 300 mg of the peptide of claim 1 in a 1 ml aqueous solution.

9. A peptide of 16 to 26 amino acid residues in length comprising the following amino acid sequence:
(a) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is W, F, Y or H; and X 6 is W, F, Y or H (SEQ ID NO:27);
(b) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is W, F, Y or H; and X 6 is K, Y, R, H, N, Q, S, or T (SEQ ID NO:28);
(c) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is W, F, Y or H; and X 6 is A, C, G, P, S, I, L, V or T (SEQ ID NO:29);
(d) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is K, Y, R, H, N, Q, S, or T; and X 6 is W, F, Y or H (SEQ ID NO:30);
(e) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is K, Y, R, H, N, Q, S, or T; and X 6 is K, Y, R, H, N, Q, S, or T (SEQ ID NO:31);
(f) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is K, Y, R, H, N, Q, S, or T; and X 6 is A, C, G, P, S, I, L, V or T (SEQ ID NO:32);
(g) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G, P, S, T; X 3 is A, I, L, P or V; X 4 is W, F, Y, H, A, I, L, P or V; X 5 is A, C, G, P, S, I, L, V or T; and X 6 is W, F, Y or H (SEQ ID NO:33);
(h) X 1 X 2 SWLRDX 3 X 4 TX 5 LQSX 6 L, wherein X 1 is A, C, G, P, S, T; X 2 is A, C, G

Assignees

• Univ Nanyang Tech

Inventors

• Cho Nam-Joon
• Jackman Joshua Alexander

Classifications

• A61P31/12

  Antivirals · CPC title

• C07K14/1833

  Hepatitis C; Hepatitis NANB · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/20

  for DNA viruses · CPC title

• C07K14/005

  from viruses · CPC title